Prevention of allergic reactions during oxaliplatin desensitization through inhibition of Bruton tyrosine kinase.

Kristin A EricksonJames E NortonJennifer LawNicole SorianoMalgorzata StrojnyNicole GentryMorgan FriedBruce S BochnerSheetal KircherWhitney W Stevens

Published in: The Journal of allergy and clinical immunology (2024)

Five doses of acalabrutinib, 100 mg, orally twice daily starting during the evening 2 days before and continuing through RDD allowed a sensitized patient to receive oxaliplatin successfully and safely.

Keyphrases

tyrosine kinase
epidermal growth factor receptor
case report
physical activity
medical education
atopic dermatitis